The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

M.M. Damirov

Kafedra akusherstva i ginekologii Rossiĭskoĭ gosudarstvennoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia, Moskva

L.G. Sozaeva

Kafedra akusherstva i ginekologii Rossiĭskoĭ gosudarstvennoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia, Moskva

T.N. Poletova

Kafedra akusherstva i ginekologii Rossiĭskoĭ gosudarstvennoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia, Moskva

Iu.E. Kizhaev

Kafedra akusherstva i ginekologii Rossiĭskoĭ gosudarstvennoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia, Moskva

V.A. Kucherov

2OOO "Bio Farma", Moskva

S.V. Stovbun

Institut khimicheskoĭ fiziki im. N.N. Semenova RAN, Moskva

D.Iu. Safronov

Institut khimicheskoĭ fiziki im. N.N. Semenova RAN, Moskva

M.I. Bagaeva

Kafedra akusherstva i ginekologii Rossiĭskoĭ gosudarstvennoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia, Moskva

Use of panavir, an antiviral drug, in the comprehensive pregravid preparation of patients with recurrent fetal loss

Authors:

M.M. Damirov, L.G. Sozaeva, T.N. Poletova, Iu.E. Kizhaev, V.A. Kucherov, S.V. Stovbun, D.Iu. Safronov, M.I. Bagaeva

More about the authors

Views: 290

Downloaded: 2


To cite this article:

Damirov MM, Sozaeva LG, Poletova TN, Kizhaev IuE, Kucherov VA, Stovbun SV, Safronov DIu, Bagaeva MI. Use of panavir, an antiviral drug, in the comprehensive pregravid preparation of patients with recurrent fetal loss. Russian Bulletin of Obstetrician-Gynecologist. 2012;12(3):79‑80. (In Russ.)

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation



We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.